ES2176106B1 - Comprimido matricial de liberacion prolongada de trimetazidina tras su administracion por via oral. - Google Patents

Comprimido matricial de liberacion prolongada de trimetazidina tras su administracion por via oral.

Info

Publication number
ES2176106B1
ES2176106B1 ES200003018A ES200003018A ES2176106B1 ES 2176106 B1 ES2176106 B1 ES 2176106B1 ES 200003018 A ES200003018 A ES 200003018A ES 200003018 A ES200003018 A ES 200003018A ES 2176106 B1 ES2176106 B1 ES 2176106B1
Authority
ES
Spain
Prior art keywords
trimetazidine
oral administration
prolonged
marriage
release compressed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200003018A
Other languages
English (en)
Other versions
ES2176106A1 (es
Inventor
De Barochez Bruno Huet
Claude Dauphant
Patrick Wuthrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Servier SAS
Original Assignee
Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9553398&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2176106(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratoires Servier SAS filed Critical Laboratoires Servier SAS
Publication of ES2176106A1 publication Critical patent/ES2176106A1/es
Application granted granted Critical
Publication of ES2176106B1 publication Critical patent/ES2176106B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Comprimido matricial de liberación prolongada de trimetazidina tras su administración por vía oral. La presente invención tiene por objeto un comprimido matricial que permite la liberación prolongada de trimetazidina o de una de sus sales de adición de un ácido farmacéuticamente aceptable después de la administración por vía oral, caracterizada porque la liberación prolongada está controlada por la utilización de un polímero derivado de celulosa.
ES200003018A 1999-12-17 2000-12-15 Comprimido matricial de liberacion prolongada de trimetazidina tras su administracion por via oral. Expired - Fee Related ES2176106B1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9915960A FR2802424B1 (fr) 1999-12-17 1999-12-17 Comprime matriciel permettant la liberation prolongee de trimetazidine apres administration par voie orale

Publications (2)

Publication Number Publication Date
ES2176106A1 ES2176106A1 (es) 2002-11-16
ES2176106B1 true ES2176106B1 (es) 2004-01-16

Family

ID=9553398

Family Applications (2)

Application Number Title Priority Date Filing Date
ES200003018A Expired - Fee Related ES2176106B1 (es) 1999-12-17 2000-12-15 Comprimido matricial de liberacion prolongada de trimetazidina tras su administracion por via oral.
ES00403533.3T Expired - Lifetime ES2240033T5 (es) 1999-12-17 2000-12-15 Comprimido matricial de liberación prolongada de trimetazidina tras su administración por vía oral

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES00403533.3T Expired - Lifetime ES2240033T5 (es) 1999-12-17 2000-12-15 Comprimido matricial de liberación prolongada de trimetazidina tras su administración por vía oral

Country Status (33)

Country Link
EP (1) EP1108424B2 (es)
JP (2) JP2001172181A (es)
KR (1) KR100456933B1 (es)
CN (1) CN1166408C (es)
AR (1) AR026968A1 (es)
AT (1) ATE296622T1 (es)
AU (1) AU780011B2 (es)
BG (1) BG65773B1 (es)
BR (1) BR0005915A (es)
CY (1) CY2347B1 (es)
CZ (1) CZ299461B6 (es)
DE (1) DE60020501T3 (es)
DK (1) DK1108424T4 (es)
EA (2) EA200501901A1 (es)
ES (2) ES2176106B1 (es)
FR (1) FR2802424B1 (es)
GE (1) GEP20053540B (es)
GR (1) GR1003658B (es)
HK (1) HK1036937A1 (es)
HU (1) HU226956B1 (es)
IE (1) IE20001017A1 (es)
IT (1) IT1317075B1 (es)
LU (1) LU90700B1 (es)
MX (1) MXPA00012462A (es)
NZ (1) NZ508912A (es)
OA (1) OA12121A (es)
PL (1) PL206994B1 (es)
PT (2) PT102542A (es)
SI (1) SI1108424T2 (es)
SK (1) SK286752B6 (es)
UA (1) UA80087C2 (es)
WO (1) WO2001043747A1 (es)
ZA (1) ZA200007548B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1195160E (pt) * 2000-10-05 2009-12-07 Usv Ltd Composições farmacêuticas de trimetazidina de libertação sustentada e método para a sua preparação
US20070092566A1 (en) 2003-08-04 2007-04-26 Ryouichi Hoshino Oral sustained-release tablet
SG126792A1 (en) * 2005-04-27 2006-11-29 Servier Lab Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral route
FR2885807B1 (fr) * 2005-05-18 2008-05-16 Mg Pharma Composition pharmaceutique solide a liberation prolongee de 1-(2,3,4-trimethoxybenzyl) piperazine, et procede de preparation
CZ300307B6 (cs) * 2006-01-04 2009-04-15 Zentiva, A. S. Tableta s obsahem trimetazidinu nebo jeho farmakologicky akceptovatelné soli s modifikovaným uvolnováním
EA009776B1 (ru) * 2006-07-18 2008-04-28 Мераб Ревазович Кокеладзе Способ изготовления таблетированной лекарственной формы триметазидина дигидрохлорида и ее состав
EA009810B1 (ru) * 2006-12-26 2008-04-28 Закрытое Акционерное Общество "Канонфарма Продакшн" Матрица для изготовления таблетированной лекарственной формы и способ лечения
EP2200591A2 (en) * 2007-09-11 2010-06-30 Ranbaxy Laboratories Limited Controlled release pharmaceutical dosage forms of trimetazidine
EP2389167A2 (en) 2009-01-20 2011-11-30 Micro Labs Limited Modified release solid pharmaceutical compositions of trimetazidine and process thereof
ES2567722T3 (es) * 2009-01-30 2016-04-26 Lupin Limited Composiciones farmacéuticas de trimetazidina
TR201001902A2 (tr) 2010-03-12 2011-04-21 Ali̇ Rai̇f İlaç Sanayi̇ Ve Ti̇caret A.Ş. Uzatılmış salınımlı trimetazidin tablet
RU2445958C2 (ru) * 2010-04-20 2012-03-27 Общество с ограниченной ответственностью "Озон" (ООО "Озон") Матричная таблетка с основой для пролонгированного высвобождения триметазидина и способ ее изготовления
ES2508490T3 (es) 2010-05-04 2014-10-16 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Formulación de trimetazidina con diferentes perfiles de liberación
EP2386302A1 (en) 2010-05-11 2011-11-16 Ranbaxy Laboratories Limited A controlled release pharmaceutical dosage form of trimetazidine and processes for the preparation thereof
EP2491930A1 (en) 2011-02-25 2012-08-29 Deva Holding Anonim Sirketi Pharmaceutical combination of betahistine and trimetazidine
FR2978916B1 (fr) * 2011-08-10 2013-07-26 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
FR2986431B1 (fr) * 2012-02-03 2017-03-17 Servier Lab Composition pharmaceutique a liberation prolongee de trimetazidine, son procede de fabrication et son utilisation dans des traitements therapeutiques
CN102824644B (zh) * 2012-09-13 2013-12-25 浙江诚意药业有限公司 使用羟丙基纤维素制备的高稳定性的缓释片
KR20160118733A (ko) 2015-04-03 2016-10-12 이인현 호스 권취용 호스 안내장치 및 이를 구비한 호스 권취기
CN109316455B (zh) * 2017-07-31 2021-05-25 北京福元医药股份有限公司 一种盐酸曲美他嗪缓释片
CN109908096A (zh) * 2017-12-12 2019-06-21 武汉武药科技有限公司 一种盐酸曲美他嗪缓释片及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4226849A (en) * 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
FR2490963B1 (fr) * 1980-09-30 1986-04-18 Science Union & Cie Nouvelle composition therapeutique a action anti-ischemique contenant de la trimethoxy 2, 3, 4-benzyl 1-piperazine
KR850006132A (ko) * 1984-02-29 1985-10-02 진 크라메르, 한스 루돌프 하우스 브로모크립틴 조성물
JPS61293931A (ja) * 1985-06-24 1986-12-24 Teijin Ltd 徐放性医薬品組成物
JPH0625055B2 (ja) * 1985-03-18 1994-04-06 日本ケミフア株式会社 持続性錠剤
EP0207638B1 (en) * 1985-06-04 1990-12-19 Teijin Limited Sustained-release pharmaceutical preparation
SE455836B (sv) * 1985-10-11 1988-08-15 Haessle Ab Beredning med kontrollerad frisettning innehallande ett salt av metoprolol samt metod for framstellning av denna beredning
SE8601624D0 (sv) * 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
FR2677886B1 (fr) * 1991-06-18 1995-03-31 Adir Comprime matriciel permettant la liberation prolongee d'indapamide apres administration par voie orale.
FR2681324B1 (fr) * 1991-09-18 1993-10-29 Adir Cie Nouveaux derives de la trimetazidine, leur procede de preparation et les compositions pharmaceutiques les contenant.
KR940021051A (ko) * 1993-03-03 1994-10-17 손정삼 3단계 약물방출형 지속성 정제
RU2082400C1 (ru) * 1993-12-16 1997-06-27 Акционерное общество - Фармацевтическая фирма "Ник-Фарм" Способ получения нитроглицерина пролонгированного действия
FR2717687B1 (fr) * 1994-03-24 1996-06-14 Adir Compositions pharmaceutiques permettant la libération prolongée de trimétazidine après administration par voie orale.

Also Published As

Publication number Publication date
JP2007314578A (ja) 2007-12-06
EA200501901A1 (ru) 2006-06-30
PL206994B1 (pl) 2010-10-29
DE60020501D1 (de) 2005-07-07
GR1003658B (el) 2001-09-05
EA008223B1 (ru) 2007-04-27
FR2802424A1 (fr) 2001-06-22
CN1302663A (zh) 2001-07-11
AU780011B2 (en) 2005-02-24
DK1108424T3 (da) 2005-10-03
EA200001201A2 (ru) 2001-08-27
SI1108424T2 (sl) 2014-02-28
MXPA00012462A (es) 2002-06-04
BG106927A (en) 2003-05-30
PT102542A (pt) 2001-06-29
ITRM20000667A0 (it) 2000-12-14
ITRM20000667A1 (it) 2002-06-14
IE20001017A1 (en) 2002-04-03
FR2802424B1 (fr) 2002-02-15
CN1166408C (zh) 2004-09-15
ATE296622T1 (de) 2005-06-15
CY2347B1 (en) 2004-06-04
DE60020501T3 (de) 2014-03-20
KR100456933B1 (ko) 2004-11-10
DE60020501T2 (de) 2006-04-27
LU90700B1 (fr) 2007-12-03
WO2001043747A8 (fr) 2001-09-07
SI1108424T1 (en) 2005-10-31
OA12121A (en) 2003-10-20
HUP0004966A2 (en) 2002-06-29
EP1108424B2 (fr) 2013-09-04
ES2176106A1 (es) 2002-11-16
JP2001172181A (ja) 2001-06-26
SK286752B6 (sk) 2009-04-06
UA80087C2 (en) 2007-08-27
CZ20022082A3 (cs) 2002-09-11
PT1108424E (pt) 2005-08-31
PL344564A1 (en) 2001-06-18
HK1036937A1 (en) 2002-01-25
BR0005915A (pt) 2001-10-02
SK8632002A3 (en) 2002-10-08
EA200001201A3 (ru) 2001-10-22
HUP0004966A3 (en) 2008-04-28
ES2240033T5 (es) 2014-01-16
BG65773B1 (bg) 2009-11-30
EP1108424A1 (fr) 2001-06-20
KR20010062478A (ko) 2001-07-07
AR026968A1 (es) 2003-03-05
WO2001043747A1 (fr) 2001-06-21
HU226956B1 (en) 2010-03-29
CZ299461B6 (cs) 2008-08-06
NZ508912A (en) 2002-04-26
EP1108424B1 (fr) 2005-06-01
IT1317075B1 (it) 2003-05-26
ES2240033T3 (es) 2005-10-16
HU0004966D0 (es) 2001-02-28
DK1108424T4 (da) 2013-12-16
AU7228500A (en) 2001-06-21
GEP20053540B (en) 2005-06-10
ZA200007548B (en) 2001-06-19

Similar Documents

Publication Publication Date Title
ES2176106B1 (es) Comprimido matricial de liberacion prolongada de trimetazidina tras su administracion por via oral.
BR9917012A (pt) Comprimido matricial, permitindo a liberação prolongada de gliclazida, após administração por via oral
CY1105120T1 (el) Η αντιμετωπιση αναπνευστικων νοσων
ES2159591T3 (es) Composicion de liberacion controlada.
AR033423A1 (es) Sales farmaceuticas constituidas de una sustancia activa farmaceutica y al menos un edulcorante, medicamentos que contienen estas sales y uso de estas sales para la preparacion de medicamentos
DE122011100049I1 (de) Stabile pharmazeutische Losungsformulierungen fur unter Druck stehende Inhaliergerate fur die Verabreichung abgemessener Dosen.
AR058433A1 (es) Derivado de 1,1-dioxido de 1,4-benzotiazepina ,procedimiento para su preparacion ,medicamentos que comprenden este compuesto y su uso
GT199800101A (es) Composicion farmaceutica solida que contiene un derivado de benzofurano.
ECSP024341A (es) Composiciones farmaceuticas
DE60235648D1 (de) Pharmazeutische metformintablette mit verlängerter freisetzung
DK0519820T3 (da) Matrixtablet, som muliggør længerevarende frigivelse af indapamid efter oral administration
AR003476A1 (es) Tabletas exentas de aglutinante que contienen tramadol o una sal de tramadol
UY26371A1 (es) Imidazo-3-il-aminas biciclicas, procedimiento para su preparacion y medicamentos que las contienen
UY27270A1 (es) Comprimido de meloxicam de rápida disgregación
CO5700723A2 (es) Uso de un derivado de amina ciclica especifico o de sus sales farmaceuticamente aceptables para tratar y prevenir la insuficiencia cardiaca
PT1425005E (pt) Composicao farmaceutica que compreende lumiracoxib
CR7648A (es) Microcapsulas para la liberacion retardada y controlada del perindropil
DE60102590D1 (de) Darreichungsformen zur behandlung von oralen mykosen
PE68199A1 (es) Composicion farmaceutica de residencia gastrica
PA8531601A1 (es) Nuevos heteroaromatos
AR023452A1 (es) Utilizacion del osanetant para preparacion de medicamentos utiles en el tratamiento de los trastornos del humor
NO20024574D0 (no) Anvendelse av CDP-kolin for behandling av alkoholabstinens
ATE357220T1 (de) Pharmazeutische zusammensetzung mit modifizierter freisetzung
ES2188232T3 (es) Uso de cetirizina para impedir la aparicion del asma.
ATE296606T1 (de) Schnell freisetzende farmazeutische darreichungsform enthaltend polymorphes tibolon

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20021116

Kind code of ref document: A1

Effective date: 20021116

FG2A Definitive protection

Ref document number: 2176106B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20180807